Pfizer NYSE:PFE delivered stronger-than-expected second-quarter results as Specialty Care and newer acquired medicines offset continued weakness across Primary Care, reinforcing the company's transition away from pandemic-era products. The split matters because Pfizer's recovery increasingly depends on specialty drugs producing enough growth to overcome declining Covid revenue and looming patent losses.

Revenue rose 3% to $15.03 billion, or 1% operationally, while adjusted earnings of 77 cents per share exceeded the 68-cent analyst consensus. Excluding Comirnaty and Paxlovid, revenue advanced 5% operationally, and recently launched and acquired products grew 18%. Pfizer also raised the midpoint of its full-year revenue guidance by $500 million to a range of $60.5 billion to $62.5 billion.

Specialty medicines supplied much of the quarter's momentum. Eliquis revenue increased 19% operationally to $2.43 billion, helped by stronger demand and favorable U.S. pricing dynamics. Cancer treatment Padcev grew 23%, heart-drug franchise Vyndaqel advanced 8%, and lung-cancer therapy Lorbrena jumped 37%. Revenue from acquired products increased 25%, providing early evidence that Pfizer's dealmaking is strengthening its commercial portfolio.

Primary Care remained the weaker side of the business. Paxlovid revenue plunged 95% operationally as infections and government purchases declined, while Comirnaty fell 34% amid lower U.S. utilization. Pfizer consequently reduced its 2026 Covid-product revenue expectation to roughly $4 billion from about $5 billion.

The company reported a four-cent GAAP loss after recording $4.3 billion of noncash intangible-asset impairments, highlighting the lingering risks attached to its acquisition strategy.

Investor Takeaway On Pfizer Stock

Investors should watch whether Specialty Care growth continues broadening beyond Eliquis and whether newer cancer products can sustain double-digit gains. Pfizer's investment case would strengthen if launched and acquired medicines keep growing near the current 18% rate while Covid declines become less material.

Key risks include additional asset write-downs, rising research spending and upcoming patent expirations. Pipeline readouts in oncology, obesity and vaccines over the next 12 months will be critical to proving that Pfizer can return to durable growth after 2028.